A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

Prior treatment

• Hospitalisation within the last 90 days before screening for hypertension or hypertensive crisis.
• A change in body weight greater than (\>) 5% within 90 days before screening irrespective of medical records.
• Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening.
• Use of any Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin agonists, within 90 days before screening.
  • For participants without T2D

Other illness

• Known secondary hypertension due to renovascular hypertension (renal artery stenosis), primary aldosteronism, Cushing's syndrome, pheochromocytoma, acromegaly, coarctation of the aorta, or any other identifiable cause of secondary hypertension.
• Currently under medical investigation for any cause of secondary hypertension.
• Atrial fibrillation at the Run-in visit or history of frequent intermittent or chronic atrial fibrillation.
• History of type 1 or type 2 diabetes mellitus.

Lab values

• Moderate-to-severe anaemia with Hgb lesser than (\<) 10.9 grams per decilitre (g/dL) as measured by the central lab at screening.
• HbA1c greater than or equal to \>= 6.5 % (48 mmol/mol) as measured by the central laboratory at screening.

Other

• Known orthostatic hypotension or orthostatic hypotension at screening (V1-Optional/V1).

• Male or female (sex at birth).
• Age 18 years or above at the time of signing the informed consent.
• Resting in-office SBP of 140-160 mmHg (both inclusive) at screening (V1-Optional/V1) and the Run-in visit. Systolic blood pressure will be calculated as the mean of the second and third consecutive readings of triplicated blood pressure readings collected at 2-minute intervals with the blood pressure monitor provided by the Sponsor.
• Body mass index greater than or equal to (\>=) 30.0 kilograms per metre square (kg/m\^2) at screening.
• Not receiving Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) or antihypertensive medication or on stable (i.e., same drug(s), dose and dosing frequency) SGLT2i or antihypertensive treatment \>= 30 days prior to screening.
  • For participants with Type 2 Diabetes (T2D)
  • The following inclusion criteria apply at screening in addition to the inclusion criteria listed above:
• Diagnosed with T2D \>= 90 days before screening.
• Glycated Haemoglobin (HbA1c) 6.5-10.0% (48-86 millimoles per mole (mmol/mol)) (both inclusive) as measured by the central laboratory at screening.
• Treatment with either lifestyle intervention only, or treatment with 1-3 marketed oral antidiabetic drugs (metformin, α-glucosidase inhibitors, glinides, SGLT2i or thiazolidinediones, as a single agent or in combination) according to local label.
• Treatment with antidiabetic medication should be stable (i.e., same drug(s), dose and dosing frequency) for at least 90 days before screening.